Last Thursday we received impressive Q2 results from one of the largest pharmaceutical companies in Eli Lilly (LLY) .  The pharma giant said its growth trajectory accelerated during Q2 as its investments in advancing innovative medicine are focused on expanding manufacturing and bringing Lilly medicines to more people worldwide.However, let’s see if it’s time to buy Eli Lilly’s stock which is up +15% since its Q2 report, to almost $900 a share.Image Source: Zacks Investment ResearchEli Lilly’s Q2 ResultsLed ...